Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMP versus Rd in transplant-ineligible newly diagnosed multiple myeloma
2017-004003-46Phase 4Active
- Sponsor
- Department of Molecular Biotechnology and Health Sciences, University of Turin
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bortezomib, melphalan, prednisone, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Department of Molecular Biotechnology and Health Sciences, University of Turin. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
bortezomibmelphalanprednisonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004003-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004003-46.